Amplification of Thymosin Beta 10 and AKAP13 Genes in Metastatic and Aggressive Papillary Thyroid Carcinomas

Abstract

Papillary thyroid carcinoma (PTC) is the most common well-differentiated thyroid cancer. Although the great majority of the cases exhibit an indolent clinical course, some of them develop local invasion with distant metastasis, and a few cases transform into undifferentiated/anaplastic thyroid carcinoma with a rapidly lethal course. To identify gene copy number alterations predictive of metastatic potential or aggressive transformation, array-based comparative genomic hybridization (CGH-array) was performed in 43 PTC cases. Formalin-fixed and paraffin-embedded samples from primary tumours of 16 cases without metastasis, 14 cases with only regional lymph node metastasis, and 13 cases with distant metastasis, recurrence or extrathyroid extension were analysed. The CGH-array and confirmatory quantitative real-time PCR results identified the deletion of the EIF4EBP3 and TRAK2 gene loci, while amplification of thymosin beta 10 (TB10) and Tre-2 oncogene regions were observed as general markers for PTC. Although there have been several studies implicating TB10 as a specific marker based on gene expression data, our study is the first to report on genomic amplification. Although no significant difference could be detected between the good and bad prognosis cases in the A-kinase anchor protein 13 (AKAP13) gene region, it was discriminative markers for metastasis. Amplification in the AKAP13 region was demonstrated in 42.9% and 15.4% of the cases with local or with distant metastasis, respectively, while no amplification was detected in non-metastatic cases. AKAP13 and TB10 regions may represent potential new genomic markers for PTC and cancer progression.

Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer

“…The role of TMSB10 in cancer is mainly related to cytoskeletal alterations. TMSB10 is part of a gene expression signature for predicting lymph node metastasis of early stage cervical carcinomas (29) and is up-regulated in metastatic papillary thyroid carcinomas (30). The roles of STMN1 and TMSB10 in breast cancer metastasis are supported by their correlation and clustering with other metastasis-associated gene products within G1 metastasis related cluster 2, e.g.…”

High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy

“…In pancreatic cancer, Tbeta10 stimulates secretion of proinflammatory cytokines interleukin (IL-7) and IL-8, which may promote pancreatic cancer pathogenesis and progression [26]. Studies on thyroid carcinoma, melanoma, non-small cell lung cancer and some other malignant tumors [21,27,28] also show that Tbeta10 possesses tumor progression properties. In the present study, we demonstrated that high expression of Tbeta10 was associated with advanced TNM stage.…”

Suppression of thymosin β10 increases cell migration and metastasis of cholangiocarcinoma

“…Expression of Tβ10 has been shown to confer cell migratory advantage in thyroid carcinoma [17,18,35,36], and melanoma [19,31,37]; but disadvantage in endothelial cells [38] and ovarian cancer [24]. However, roles of Tβ10 in cancer development such as cell growth and apoptosis still remain controversial among cancers [15,16].…”